Lincoln Pharmaceuticals Limited has informed the Exchange about General Updates Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has completed the trial run of its new manufacturing facility at Khatraj, Gandhinagar, Gujarat, which will produce Active Pharmaceutical Ingredients (APIs). The facility proposes to add 1.2 tonnes per annum of capacity, with commercial production expected to begin in 1 to 2 years, subject to product approvals from the Food & Drugs Control Administration. The project requires an investment of approximately INR 4 crore, funded entirely through internal accruals. The company stated the rationale is to cater to additional market demand and support internal consumption. Currently, the facility has no existing capacity as it is in the trial run phase.
This is a modest, self-funded capacity expansion in APIs that should reduce dependence on third-party API suppliers over time. However, commercial production is 1-2 years away and depends on regulatory approvals, so any positive impact on revenue and margins will be gradual rather than immediate.